Heron Therapeutics, Inc. 0J4V.L Stock
Heron Therapeutics, Inc. Price Chart
Heron Therapeutics, Inc. 0J4V.L Financial and Trading Overview
Heron Therapeutics, Inc. stock price | 2.95 USD |
Previous Close | 1.29 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 5.54 USD |
Volume | 3.8K USD |
Avg. Volume | 9.91K USD |
Market Cap | 1M USD |
Beta (5Y Monthly) | 0.927464 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.293 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0J4V.L Valuation Measures
Enterprise Value | 247.73M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.008817878 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.176 |
Enterprise Value/EBITDA | -1.815 |
Trading Information
Heron Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.927464 |
52-Week Change | -55.59% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.54 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 1.88 USD |
200-Day Moving Average | 2.77 USD |
0J4V.L Share Statistics
Avg. Volume (3 month) | 9.91K USD |
Avg. Daily Volume (10-Days) | 6.41K USD |
Shares Outstanding | 78.02M |
Float | 98.86M |
Short Ratio | N/A |
% Held by Insiders | 0.31% |
% Held by Institutions | 102.54% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -132.57% |
Operating Margin (ttm) | -122.46% |
Gross Margin | -42.36% |
EBITDA Margin | -119.92% |
Management Effectiveness
Return on Assets (ttm) | -35.22% |
Return on Equity (ttm) | -2408.87% |
Income Statement
Revenue (ttm) | 113.83M USD |
Revenue Per Share (ttm) | 1.01 USD |
Quarterly Revenue Growth (yoy) | 26.30% |
Gross Profit (ttm) | -50508000 USD |
EBITDA | -136512000 USD |
Net Income Avi to Common (ttm) | -150904000 USD |
Diluted EPS (ttm) | -2.293 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 60.02M USD |
Total Cash Per Share (mrq) | 0.5 USD |
Total Debt (mrq) | 156.93M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.287 |
Book Value Per Share (mrq) | -0.096 |
Cash Flow Statement
Operating Cash Flow (ttm) | -127873000 USD |
Levered Free Cash Flow (ttm) | -69407624 USD |
Profile of Heron Therapeutics, Inc.
Country | United Kingdom |
State | CA |
City | San Diego |
Address | 4242 Campus Point Court |
ZIP | 92121 |
Phone | 858 251 4400 |
Website | https://www.herontx.com |
Industry | |
Sector(s) | |
Full Time Employees | 203 |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Q&A For Heron Therapeutics, Inc. Stock
What is a current 0J4V.L stock price?
Heron Therapeutics, Inc. 0J4V.L stock price today per share is 2.95 USD.
How to purchase Heron Therapeutics, Inc. stock?
You can buy 0J4V.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Heron Therapeutics, Inc.?
The stock symbol or ticker of Heron Therapeutics, Inc. is 0J4V.L.
How many shares does Heron Therapeutics, Inc. have in circulation?
The max supply of Heron Therapeutics, Inc. shares is 796.68K.
What is Heron Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Heron Therapeutics, Inc. PE Ratio is now.
What was Heron Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Heron Therapeutics, Inc. EPS is -2.293 USD over the trailing 12 months.